Together for
enhancing knowledge
Insights
Brochures
Snapshot of end-to-end safety services across the drug development lifecycle.
Videos
Perspectives by leadership team on drug safety, ensuring compliance and emerging therapies.
Case Studies
Learn more about how we delivered exceptional value to our customers across the product lifecycle.
Whitepapers/ Articles
Subject matter experts share their views on patient safety and emerging therapies.
Blogs
Point of view on the aspects of drug safety, regulations and organizational excellence.
Infographics
Visual representation of scientific and medical knowledge around drug safety and emerging therapies.
Suggested Content
COVID-19: Patients’ Safety First
The ongoing COVID-19 outbreak has affected millions of people globally. Governments, public health agencies, pharmaceutical companies, healthcare and research organizations are pursuing the common purpose to contain further spread and develop safe and effective treatment and preventive measures at the earliest.
Currently, there are no specific vaccines, biologics or drugs for prevention or treatment for COVID-19. Multiple therapeutic modalities including vaccines, immunomodulators and drugs are being investigated at a large scale for potential effectiveness against the virus. The pandemic paradigm requires multiple activities to be conducted at financial risk to developers and manufacturers and without knowing whether the vaccine candidate will be safe and effective. Effective benefit risk analysis of these therapies acts as a backbone to ensure fast track movement of the product across various stages from clinical trials to commercialization.
APCER Life Sciences is committed to the safety of its people and is prepared to support companies dedicated towards developing vaccines and treatments for this disease.